Inactive Instrument

Cambrex Corporation

CBM

Cambrex Corporation Appoints Bernhard Hampl to Board of Directors

October 31, 2016 at 10:45 am

Cambrex Corporation announced that Bernhard Hampl was appointed to the Company’s Board of Directors on October 27, 2016, and will serve on the Board’s Regulatory Affairs Committee. Dr. Hampl’s appointment increases the size of the Board to ten members. Dr. Hampl is the President of BKH Pharma Services, a pharmaceutical consultancy firm.

Latest news about Cambrex Corporation

Noramco, Inc. acquired Drug Product Business Unit of Cambrex Corporation.	11-01	CI
Noramco, Inc. acquired Halo Pharma, Inc. from Cambrex Corporation.	11-01	CI
Cambrex Announces Grand Opening of New First Stability Storage Commercial Agreement	31/05/23	CI
Cambrex Opens New Stability Storage Facility in Belgium	04/04/23	CI
Cambrex Corporation completed the acquisition of Snapdragon Chemistry, Inc.	17/01/23	CI
Cambrex Corporation entered into a definitive agreement to acquire Snapdragon Chemistry, Inc.	20/11/22	CI
Cambrex to Invest $16.5 Million in New R&D Facility in Minneapolis, Minnesota and Expansion in Charles City, Iowa	27/10/22	CI
Cambrex Corporation Announces Stability Storage Expansions in Ireland and Belgium	04/10/22	CI
Cambrex Completes First Phase of $30 Million Capacity Expansion Project in High Point, North Carolina	01/09/22	CI
Cambrex Corporation acquired Q1 Scientific Limited.	31/05/22	CI
Cambrex Completes Large-Scale US API Expansion	12/04/22	CI
Cambrex Corporation Expands Biopharmaceutical Services Business	01/03/22	CI
Cambrex to Invest $30 Million to Expand Manufacturing Center of Excellence At High Point, NC Facility	07/10/21	CI
Omega Therapeutics Expands Board of Directors with Appointment of Luke Beshar	23/06/21	CI
Cambrex Introduces New Kilogram-Scale Gmp Manufacturing Capabilities At Tallinn, Estonia Facility	26/05/21	CI
Cambrex Expands Analytical Services Capabilities at Longmont, Colorado, Facility	05/05/21	CI
Cambrex to Invest $50 Million to Expand Multipurpose Large-Scale Manufacturing Capabilities in the U.S	17/11/20	CI
Cambrex Completes Major Expansion of Solid Form Screening Facility in Edinburgh	12/10/20	CI
Cambrex Increases Flexible Manufacturing Capacity at Karlskoga, Sweden Facility	01/07/20	CI
Cambrex Appoints Thomas Loewald as Member of the Board of Directors Effective September 7, 2020	18/06/20	CI
Cambrex Appoints Thomas Loewald as Chief Executive Officer Effective September 7, 2020	18/06/20	CI
Cambrex Announces Management Changes	02/06/20	CI
Cambrex Announces Board Changes	02/06/20	CI
Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility	07/04/20	CI
Cambrex Appoints Troy Player as President, Early Stage Development and Testing	31/03/20	CI

Chart Cambrex Corporation

Duration

Period

More charts

Company Profile

Cambrex Corporation (Cambrex) is a United States-based small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. The Company offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and potent application program interface. In addition, it also supports conventional dosage forms including oral solids, semi-solids and liquids and has the capabilities to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals